OrbiMed Debuts $222M Israeli Life Sciences Venture Fund

Law360, New York (April 23, 2012, 5:08 PM EDT) -- Investment management firm OrbiMed Advisors LLC on Monday launched a $222 million venture capital fund aimed at beefing up its portfolio with Israeli life sciences companies in a sector fund managers say is coming of age.

The fund, dubbed OrbiMed Israel Partners LP, will target biotechnology, pharmaceutical, medical device and diagnostics companies at varying stages of maturity, from seed stage through growth equity, according to a statement the firm issued Monday.

The fund's first close of $222 million includes an anchor investment from the Israeli government,...
To view the full article, register now.